AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Platelet Aggregation Inhibitors (P2Y 12-receptor antagonists)

Platelet aggregation inhibitors: Novel antagonists of the P2Y12-receptor with antithrombotic effect.
Technology Benefits
Innovative group of compounds for a validated target
No bioactivation for faster onset of action
Reversible binding to the receptor
Small molecules for inexpensive production process
Technology Application
Drug discovery, Modulation of P2 receptors in platelets is of paramount importance in regulating platelet function, and, as a consequence, in controlling thrombotic diseases,
Detailed Technology Description
The P2Y12-receptor on blood platelets is the target of known antithrombotic drugs (e.g. clopidogrel). The receptor is therefore validated for this therapeutic use. Furthermore, the P2Y12-receptor is expressed in certain parts of the brain, which opens new routes for the treatment of neuroinflammatory and neurodegenerative diseases. This invention provides novel antagonists of the P2Y12-receptor. The disclosed novel compounds show reversible and selective binding to the P2Y12-receptor. The molecules do not require bioactivation.
Type of Cooperation
Application Date
07/03/2008 00:00:00
Application No.
EP20080735068 20080307
- international:
A61K31/136; A61P7/02; A61P9/10; C07C229/74; C07C309/46; C07C309/53; C07C323/37; C07D239/42; C07D251/42; C07D251/44; C07D251/46; C07D251/50
- cooperative:
C07C229/74; C07C309/46; C07C309/53; C07C323/37; C07D251/42; C07D251/44; C07D251/46; C07D251/50; C07C2603/24
Patent application
ID No.

For more information, please click Here
Mobile Device